Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

2 Followers

BROOKS Stock Chart & Stats

₹123.65

-₹3.80(-2.00%)

At close: Jan 09 4:00 PM EST

₹123.65

-₹3.80(-2.00%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume3.81K

Average Volume (3M)2.20K

Market Cap

₹2.03B

Enterprise Value₹1.98B

Total Cash (Recent Filing)₹18.03M

Total Debt (Recent Filing)₹78.33M

Price to Earnings (P/E)8.2

Beta1.66

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.97

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.89

Price to Sales (P/S)1.27

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative LeverageVery low debt-to-equity (~0.07) gives durable financial flexibility: limited interest burden, capacity to absorb shocks, and optionality for targeted R&D or bolt-on deals without stressing liquidity. This structural conservatism supports stability over the next several quarters.

Profitability ReboundA sharp return to positive earnings power with ~29% net margin and ~20% ROE indicates the business can generate strong returns when revenue stabilizes. Sustained margins improve reinvestment capacity and create a structural cushion against industry headwinds.

Improving Cash GenerationTransitioning from multi-year cash outflows to positive operating and free cash flow represents a durable improvement in financial health. Even if conversion remains imperfect, the firm now has more internal funding for capex, working capital, or deleveraging.

Bears Say

Sharp FY2026 Revenue DeclineA ~23% top-line drop is a material structural risk: lower scale can erode gross margins, reduce pricing power, and magnify fixed-cost leverage. Sustained revenue weakness would threaten the recent profit rebound and limit durable growth prospects over the medium term.

Weak Cash ConversionOperating cash flow covering under 50% of net income signals earnings quality issues and reliance on accruals. If cash conversion does not improve, the company may struggle to fund sustained growth or return capital without external financing, raising structural liquidity risk.

Historical Margin Volatility And Prior LossesMulti-year volatility and past negative gross margins indicate execution and pricing vulnerability. This history of swings increases the probability that the current margin peak may not persist, complicating long-term planning and making outcomes more binary for investors.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

9M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹2.03B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Aug 07, 2026 which is in 37 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹0.52 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.52.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹0.52 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.998%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product portfolio includes carbapenem medications, various tablets, dry syrups, both liquid and powdered injectable solutions, and specialized eye and ear drops. Brooks Laboratories Limited was established in 2002 and is headquartered in Mumbai, India.